SQLite Web: event_store.db

Update row 13889 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:1dcea0ee99e524b0","evidence_event_ids":["evt_fc89ee338f38"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","company":"Sonoma Pharmaceuticals, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_7645eeca37ea44e4","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:34:49.399251+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"Sonoma Pharmaceuticals, Inc. 8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt","source_event_id":"evt_fc89ee338f38","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"0f982101075273d1","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-08","2026-04-09","2026-04-10","2025-10-24","2027-03"],"entities":[{"asset_class":"equity","name":"Sonoma Pharmaceuticals, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"private_company","name":"Kenvue Brands LLC","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"product","name":"Microcyn\u00ae technology-based products","relevance":"medium","symbol":"","type":"product"}],"event_type":"listing","information_gaps":["The specific SEC Item(s) triggering the 8-K are not provided in the cleaned text (Item hints/material items are empty).","Financial terms (e.g., Price, minimums, volumes, royalties, payment terms) are not disclosed in the provided excerpt; Exhibit 10.1 content is partially excluded.","The prior known state and what changed vs prior filings is not included in the provided text, so the delta cannot be fully determined beyond the fact that this 8-K was filed."],"key_facts":["Form 8-K filed with the SEC by Sonoma Pharmaceuticals, Inc.","Date of earliest event reported: April 8, 2026.","On April 8, 2026, Sonoma entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn\u00ae technology-based products in the United States.","Agreement effective date: October 24, 2025.","Agreement term: through March 2027.","Agreement may be extended by up to two additional one-year terms upon mutual written agreement.","The agreement is filed as Exhibit 10.1.","Certain identified information in Exhibit 10.1 was excluded because it is not material and is treated as private or confidential."],"numeric_claims":[{"label":"Agreement effective date","value":"October 24, 2025"},{"label":"Agreement end date","value":"March 2027"},{"label":"Potential extension length","value":"up to two additional one-year terms"}],"primary_claim":"On April 8, 2026, Sonoma Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn\u00ae technology-based products in the United States, effective October 24, 2025 through March 2027.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Sonoma Pharmaceuticals, Inc. filed a Form 8-K reporting it entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for Microcyn\u00ae technology-based products in the U.S. The agreement is effective October 24, 2025 through March 2027, with potential extensions.","topics":["SEC filing","8-K","Manufacturing and Supply Agreement","Microcyn technology","Exhibit 10.1"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Sonoma Pharmaceuticals, Inc. \u00b7 Filed 20260409","ticker":"SNOA","tickers":["SNOA"],"title":"SNOA filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-002761.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel